TNFRSF10A and Miyoshi myopathy: More interestingly, while 24 hour bortezomib treatment (10nM) could successfully upregulate TRAIL-R1 expression in MM cells of patients without del(8)(p21) (1.31 fold, p = 0.0059), MM cells from patients with del(8)(p21) failed to upregulate the pro-apoptotic TRAIL-R1 expression (1.11 fold, p = 0.1254) (Fig 3A).